Combined Phase 3 Double-blind Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn s Disease

Brief description of study

The purpose of this study is to see if filgotinib is effective and safe in treating people with moderate to severe Crohn’s disease. The study drug, filgotinib, is considered investigational in this study. Investigational means that the drug has not been approved by the Food and Drug Administration (FDA). Filgotinib is a selective JAK1 inhibitor. JAK1 is a protein inside certain cells(including immune cells) that may stimulate their activity. When immune cells are overactive, they can cause abdominal pain and diarrhea in Crohn’s disease patients. JAK1 inhibitors are believed to slow down the activity of the immune cells.


Clinical Study Identifier: s17-00389
ClinicalTrials.gov Identifier: NCT02914561
Principal Investigator: David P Hudesman.
Other Investigator: Shannon Chang.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.